Inogen Inc
$ 6.82
3.49%
17 Apr - close price
- Market Cap 179,461,000 USD
- Current Price $ 6.82
- High / Low $ 6.92 / 6.62
- Stock P/E N/A
- Book Value 7.06
- EPS -0.86
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.12 %
- 52 Week High 9.13
- 52 Week Low 5.34
About
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Analyst Target Price
$12.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-04 |
| Reported EPS | -0.15 | -0.2 | -0.15 | -0.11 | -0.24 | -0.25 | -0.24 | -0.62 | -1.14 | -0.55 | -0.42 | -0.88 |
| Estimated EPS | -0.3424 | -0.21 | -0.27 | -0.25 | -0.49 | -0.49 | -0.55 | -0.76 | -0.62 | -0.49 | -0.59 | -0.81 |
| Surprise | 0.1924 | 0.01 | 0.12 | 0.14 | 0.25 | 0.24 | 0.31 | 0.14 | -0.52 | -0.06 | 0.17 | -0.07 |
| Surprise Percentage | 56.1916% | 4.7619% | 44.4444% | 56% | 51.0204% | 48.9796% | 56.3636% | 18.4211% | -83.871% | -12.2449% | 28.8136% | -8.642% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INGN
2026-04-08 20:39:36
Inogen Inc.'s EVP, CFO & Treasurer, Jason Andrew Richardson, has been listed in a new Form 3 insider report, which is an initial statement of beneficial ownership. The filing indicates no reported buy or sell transactions, derivativepositions, or other related activities, reflecting a neutral impact and sentiment. This Form 3 establishes his initial ownership status as an insider at Inogen Inc., with no current beneficial ownership of securities listed.
2026-04-08 20:39:36
Inogen Inc. granted its EVP, CFO, and Treasurer, Jason Andrew Richardson, 100,000 restricted stock units (RSUs) on April 6, 2026. These RSUs, each representing a contingent right to one share of Inogen common stock, will vest over three years. One-third of the units vest one year from June 1, 2026, with the remaining portions vesting in equal annual installments, contingent on continued service.
2026-04-08 16:39:36
Freedom Broker has initiated coverage on Inogen Inc (NASDAQ: INGN) with a "Buy" rating and a $12 price target, indicating a nearly 100% upside from its current trading price of $6.36. Inogen specializes in portable oxygen concentrators for chronic respiratory conditions, a market driven by an aging population and increasing demand for home-based care. The company's expansion into CPAP and stationary units, along with analysts' consensus for significant upside potential, suggests a promising outlook despite competitive risks and potential reimbursement changes.
2026-04-08 15:09:58
Inogen (INGN) shares surged 6.9% on higher-than-average volume, driven by a "Buy" rating and optimistic price target from Freedom Broker, as well as recent governance improvements. While the company anticipates a 4% year-over-year increase in quarterly earnings and a 0.2% rise in revenue, the consensus EPS estimate for the quarter has remained unchanged. Investors are advised to monitor INGN closely for sustained strength, as the stock currently holds a Zacks Rank #3 (Hold).
2026-04-07 14:13:49
Inogen, Inc., a medical technology company, announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective on the date of the Company’s 2026 Annual Meeting. Jamali, a seasoned medical device executive with experience at ZimVie, Covidien, and Medtronic, is expected to bring valuable expertise to help Inogen transition into a diversified respiratory care platform. The appointment is part of a cooperation agreement with Kent Lake Partners LP, which has expressed confidence in Inogen's strategic direction emphasizing organic growth, profitability, innovation, and capital allocation.
2026-04-07 11:09:18
Inogen, Inc. has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective either on June 15th or the date of the Company’s 2026 Annual Meeting. Jamali brings extensive experience as a medical device executive, having previously served as CEO of ZimVie and held senior roles at Covidien and Medtronic. This appointment is expected to support Inogen's strategic transformation from a single-product oxygen company into a diversified respiratory care platform, focusing on growth, profitability, and product innovation.
